Arrowhead Pharmaceuticals (ARWR)

Executive Summary

Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary TRiM™ RNAi platform to develop tissue-specific therapies for genetically driven diseases. The platform enables targeted silencing of disease-causing genes, with a focus on cardiovascular and metabolic disorders. Arrowhead's lead candidate, plozasiran (ARO-APOC3), is in Phase 3 trials for hypertriglyceridemia and familial chylomicronemia syndrome (FCS). Positive data from these studies could support regulatory filings, potentially expanding treatment options for patients with severe hypertriglyceridemia. The company also has early-stage programs in complement-mediated diseases and other indications, underscoring its pipeline breadth. With a strong balance sheet and a validated platform, Arrowhead is positioned to address significant unmet medical needs in genetic disorders.

Upcoming Catalysts (preview)

• Q2 2026Plozasiran Phase 3 FCS Data Readout (PALISADE)80% success
• Q3 2026Plozasiran Phase 3 SHTG Data Readout (SHASTA-3)75% success
• Q1 2027Regulatory Submission for Plozasiran in FCS (if data positive)70% success